GeneTether Therapeutics IncCanadian Securities Exchange:GTTX
- LAST PRICE0.1000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.1000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GTTX |
|---|---|---|
| 12:42 ET | 500 | 0.1 |
| 03:39 ET | 1000 | 0.1 |
Nov 22, 2024
GeneTether Therapeutics Inc. Announces Third Quarter 2024 Financial Results, from 6:21PM ET on Friday Nov 22, 2024 by Dow Jones
6:21PM ET on Friday Nov 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
GeneTether Therapeutics Inc | 3.9M | -4.7x | --- |
Quest Pharmatech Inc | 5.9M | 0.4x | --- |
Rakovina Therapeutics Inc | 5.0M | -1.3x | --- |
Awakn Life Sciences Corp | 5.0M | -1.3x | --- |
Glow Lifetech Corp | 6.7M | -1.6x | --- |
Revive Therapeutics Ltd | 4.2M | -0.7x | --- |
Company Information
GeneTether Therapeutics Inc. is a Canada-based genetic medicines company focused on creating gene editing therapies based on its proprietary GeneTether platform. The Company's platform technology uses a proprietary method to tether donor deoxyribonucleic acid (DNA) templates to the genome editing complex, making the template readily available for use during the genome editing repair stage. By positioning a donor DNA template directly at the site of a double strand break, the Company's GeneTether platform drives the DNA repair process towards homology-directed repair (HDR), a cellular repair mechanism that incorporates the genetic information of a DNA template. It is building a discovery pipeline focused on the treatment of rare, monogenic diseases of the kidney and the skin. The Company's GeneTether platform may also allow for high fidelity engineering of cells to permanently deliver the therapeutic proteins necessary to treat certain genetic diseases.
Contact Information
- Headquarters
- c/o Pushor Mitchell LLP 301-1665 Ellis StreetKELOWNA, BC, Canada V1Y 2B3
- Phone
- 250-869-1195
- Fax
- ---
Executives
- Director
- Daren Graham
- Chief Executive Officer, Director
- Roland Boivin
- Co-Founder, Executive Director
- William Garner
- Chief Financial Officer, Corporate Secretary
- Jean Jen
- Independent Director
- Andre Pereira Fraga Figueiredo
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 38.7M |
GeneTether Therapeutics Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.02 |
Book Value | $0.05 |
P/E Ratio | -4.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
